Stent

CryoLife Receives CE Mark for E-nside Thoraco-abdominal Stent Graft

Retrieved on: 
Monday, December 2, 2019
Interventional radiology, Stent, Medicine

E-nside is the Company's newest proprietary endovascular stent graft for patients suffering from thoraco-abdominal aortic disease.

Key Points: 
  • E-nside is the Company's newest proprietary endovascular stent graft for patients suffering from thoraco-abdominal aortic disease.
  • "We are pleased to have received CE Mark for E-nside, the only off-the-shelf pre-cannulated thoraco-abdominal stent graft with inner branches.
  • The CE mark for E-nside positions CryoLife well in the EU aortic stent graft market due to JOTEC's E-xtra Design Engineering program which provides patient-specific solutions, as well as due to the synergies between E-nside and JOTEC's existing portfolio of thoracic and abdominal stent grafts.
  • The E-nside stent graft system will be manufactured at the Company's facility in Hechingen, Germany.

Stents Market Value to Hit $14 Billion by 2025: Global Market Insights, Inc.

Retrieved on: 
Tuesday, November 26, 2019
Medical devices, Interventional radiology, Stent, Interventional cardiology, Terumo, Health care

SELBYVILLE, Del., Nov. 26, 2019 /PRNewswire/ -- Global Stents market revenue is set to surpass USD $14 billion by 2025, according to a new research report by Global Market Insights, Inc.

Key Points: 
  • SELBYVILLE, Del., Nov. 26, 2019 /PRNewswire/ -- Global Stents market revenue is set to surpass USD $14 billion by 2025, according to a new research report by Global Market Insights, Inc.
  • Technological advancements will also play a significant role in the global stents industry's expansion in the future.
  • Some major findings of the stents market report include:
    Major players operating in the stents market include Abbott Laboratories, B. Braun, Boston Scientific, Terumo, and Elixir Medical Corporation
    Based on products, the stents market is bifurcated into vascular and non-vascular stents.
  • Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider, offering syndicated and custom research reports along with growth consulting services.

Merit Medical Receives FDA Breakthrough Device Designation for WRAPSODY™ Endovascular Stent Graft System

Retrieved on: 
Thursday, November 21, 2019
Interventional radiology, Health, Stent, Food and Drug Administration, Medicine

SOUTH JORDAN, Utah, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the Merit WRAPSODY Endovascular Stent Graft System.

Key Points: 
  • SOUTH JORDAN, Utah, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the Merit WRAPSODY Endovascular Stent Graft System.
  • The FDA Breakthrough Devices Program is intended to help patients receive more timely access to breakthrough technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
  • Under the program, the FDA provides priority review and interactive communication regarding device development and clinical trial protocols, through to commercialization decisions.
  • The WRAPSODY system is nearing completion of its First in Man studies, and is not currently available for sale.

Global Bioresorbable Vascular Scaffold Markets 2017-2019 & 2027 - World Market Projected to Rise at a CAGR of 10.3% During 2019-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 20, 2019
Medical devices, Health, Interventional radiology, Stent

The "Global Bioresorbable Vascular Scaffold Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bioresorbable Vascular Scaffold Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The bioresorbable vascular scaffold market was valued at US$ 165.8 Mn in 2018, expected to grow at a CAGR of 10.3% during the forecast period from 2019 to 2027.
  • The global bioresorbable vascular scaffold market is increasing efficiently from 2019 to 2027 accredited to increase in hospital admissions for heart-related disorders along with enhanced biosynthetic and polymer technology in the stent industry globally.
  • An increasing number of partnerships and mergers with medical technology organizations and research institutes internationally will boost market growth internationally.

Global Bio-Engineered Stent Report 2019: Market Size & Share (2017-2027), Application Analysis, Growth Trends, Key Players, Competitive Strategies - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 20, 2019
Health, Biotechnology, Medical technology, Medical devices, Interventional cardiology, Medicine, Medical equipment, Biotronik, Cardiac electrophysiology, Stent, Coronary stent, Drug-eluting stent, Percutaneous coronary intervention

The "Global Bio-Engineered Stent Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Bio-Engineered Stent Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global bio-engineered stent market is growing effectively from 2019 to 2027, accredited to the rise in hospital admissions for heart disorders along with enhanced bioengineered technology expansion in the stent industry on a global scale.
  • In September 2018, Biotronik received the U.S FDA approval for coronary stent system for the management of acute coronary artery.
  • A growing number of clinical trials for future launch by global players expected to drive the growth of the market in the near future.

Shockwave Initiates Study of Coronary Intravascular Lithotripsy in Japan

Retrieved on: 
Thursday, November 7, 2019
Medicine, Cardiovascular system, Circulatory system, Interventional radiology, Medical devices, Coronary artery disease, RTT, Stent, Coronary

DISRUPT CAD IV is a prospective, multicenter, single-arm study to demonstrate the safety and effectiveness of the Shockwave Coronary IVL System with the Shockwave C2 IVL Catheter in the treatment of de novo, calcified, stenotic, coronary arteries prior to stenting.

Key Points: 
  • DISRUPT CAD IV is a prospective, multicenter, single-arm study to demonstrate the safety and effectiveness of the Shockwave Coronary IVL System with the Shockwave C2 IVL Catheter in the treatment of de novo, calcified, stenotic, coronary arteries prior to stenting.
  • The study is expected to enroll up to 64 patients at 8 sites in Japan.
  • We are honored to initiate the clinical investigation of coronary IVL in Japan to evaluate calcium modification, said Dr. Saito.
  • Shockwave C2 Coronary IVL catheters are commercially available for the treatment of de novo coronary artery disease in Europe and other select countries; in Japan they are limited to investigational use within the DISRUPT CAD IV Study.

VIVA Presentation Supports Zilver® PTX® Benefits Across Different Patient Groups

Retrieved on: 
Wednesday, November 6, 2019
General Health, Health, Medical devices, Organic compounds, RTT, Interventional radiology, Medical devices, Paclitaxel, Taxanes, PTX, Peripheral artery disease, Stent

At this years Vascular Interventional Advances (VIVA) conference, Dr. Michael D. Dake presented data on Zilver PTX that supports the devices benefits across different patient groups.

Key Points: 
  • At this years Vascular Interventional Advances (VIVA) conference, Dr. Michael D. Dake presented data on Zilver PTX that supports the devices benefits across different patient groups.
  • At VIVA, Dr. Dake presented the latest data regarding Zilver PTX, Cook Medicals paclitaxel-coated stent that is used to treat peripheral arterial disease (PAD).
  • His presentation focused on findings that Zilver PTX shows benefits for a variety of patients.
  • The patient-level data, as well as Dr. Dakes VIVA presentation and other Zilver PTX information, are available at https://www.cookmedical.com/peripheral-intervention/paclitaxel/ .

Coronary Stents Market Value to Hit $8 Billion by 2025: Global Market Insights, Inc.

Retrieved on: 
Wednesday, November 6, 2019
Interventional cardiology, Medicine, Medical technology, Medical devices, Medical equipment, Drug-eluting stent, Coronary stent, Stent, Medtronic, Percutaneous coronary intervention, Bare-metal stent

Increasing technological advancements associated with coronary stents, such as bifurcated stents and use of biodegradable materials are expected to prompt a rise in the market value.

Key Points: 
  • Increasing technological advancements associated with coronary stents, such as bifurcated stents and use of biodegradable materials are expected to prompt a rise in the market value.
  • Major players operating in the market are focusing primarily on design innovations to modify the stents as per patient's condition.
  • For instance, in February 2018, Medtronic plc announced the launch of Resolute Onyx 2.0 mm Drug-Eluting Stent (DES); the smallest DES in the coronary stents market.
  • Global Market Insights, Inc., headquartered in Delaware, U.S., is a global market research and consulting service provider; offering syndicated and custom research reports along with growth consulting services.

Five More Late-Breaking Clinical Trials Announced at VIVA19

Retrieved on: 
Tuesday, November 5, 2019
Interventional radiology, Stent

To investigate the longer-term durability of the endovascular approach, the 24-month VMI-CFA study results were prospectively analyzed.

Key Points: 
  • To investigate the longer-term durability of the endovascular approach, the 24-month VMI-CFA study results were prospectively analyzed.
  • A head-to-head randomized controlled trial of Supera vs endarterectomy (SUPERSURG RCT) will be launched in 2020 to further clarify the CFA treatment discussion.
  • Two-year results from a prospective multicenter premarket study including 25 patients (mean age, 73 years) treated with Nexus are presented.
  • Nexus is a modular stent graft introduced via a 20-F delivery system with double flushing ports, which allows efficient de-airing.

Boston Scientific Announces Positive Data for the Ranger™ Drug-Coated Balloon and the Eluvia™ Drug-Eluting Vascular Stent at VIVA19

Retrieved on: 
Tuesday, November 5, 2019
Medical devices, Boston Scientific, Stent, Life sciences, Biotechnology, Industries

"The high primary patency rate as well as the significantly lower TLR rate, which reduces the need for repeat procedures, are very encouraging."

Key Points: 
  • "The high primary patency rate as well as the significantly lower TLR rate, which reduces the need for repeat procedures, are very encouraging."
  • The RANGER DCB gained CE Mark in 2014 and the company submitted for U.S. Food and Drug Administration approval of the device earlier this year.
  • The combination of the RANGER DCB as well as the Eluvia stent positions Boston Scientific as the only company to have both a DES and a DCB for the treatment of PAD in their portfolio.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.